<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01006798</url>
  </required_header>
  <id_info>
    <org_study_id>PXVX-H5-103-001</org_study_id>
    <nct_id>NCT01006798</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1</brief_title>
  <official_title>Phase 1 Evaluation of the Safety and Immunogenicity of a Replication-Competent Adenovirus Serotype 4-vectored H5N1 Influenza Candidate Vaccine - Ad4-H5-Vtn</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PaxVax, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PaxVax, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and immunogenicity over a 9-month period
      of five different dosages of Ad4-H5-Vtn in volunteers (Vaccinees) who receive three doses of
      the study vaccine or placebo. In addition, transmission of Ad4-H5-Vtn will be evaluated in
      all Household Contacts residing with the vaccinated volunteers.

      Vaccinees also may participate in a substudy in which they receive a booster vaccination with
      the licensed Influenza Virus Vaccine, H5N1 (Sanofi Pasteur).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At least 160 healthy Vaccinees will be randomized into 5 ascending dosage cohorts each
      consisting of at least 32 volunteers. In each dosage cohort Vaccinees will be randomly
      assigned to receive 3 doses of either Ad4-H5-Vtn or placebo separated by approximately 56
      days. Volunteers will be followed for 168 days post-third vaccination.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety, defined as the frequency and severity of vaccine-related reactogenicity events and reported AEs</measure>
    <time_frame>Throughout trial (reactogenicity for 7 days following each vaccination)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity (humoral) defined by H5 HAI titer</measure>
    <time_frame>At all available timepoints</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity (humoral), defined by Ad4 antibody response</measure>
    <time_frame>At all available timepoints</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Replication/excretion of Ad4-H5-Vtn virus</measure>
    <time_frame>Throughout trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transmission to household contacts as measured by AE assessment and antibody response and viral replication/excretion</measure>
    <time_frame>Throughout trial</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">166</enrollment>
  <condition>Bird Flu</condition>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>three vaccinations of 10^7vp Ad4-H5-Vtn or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>three vaccinations of the 10^8vp Ad4-H5-Vtn or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>three vaccinations of 10^9 Ad4-H5-Vtn or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>three vaccinations of 10^10 Ad4-H5-Vtn or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>three vaccinations of 10^11 Ad4-H5-Vtn or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>enteric coated capsule containing no vaccine virus</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <other_name>Placebo for Ad4-H5-Vtn</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ad4-H5-Vtn</intervention_name>
    <description>a live, replication-competent, recombinant Ad4 virus expressing the HA of H5N1 influenza (A/Vietnam/1194/2004) in an enteric capsule for oral administration</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <other_name>Adenovirus Serotype 4-vectored H5N1 Influenza Vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Sanofi Pasteur Influenza Virus Vaccine, H5N1</intervention_name>
    <description>Single administration of a heterologous boost given to volunteers 3 to 15 months following their last vaccination with Ad4-H5-Vtn or placebo.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <other_name>FDA-licensed inactivated monovalent Influenza Virus Vaccine, H5N1</other_name>
    <other_name>licensed H5N1 vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adults and their healthy adult household contacts.

        Exclusion Criteria:

          -  Healthcare workers who have direct contact with patients who are immunodeficient, are
             HIV-positive, have an unstable medical condition, or are under the age of 18.

          -  Childcare workers who have direct contact with children 5 years old and younger.

          -  Resides with Household Contacts who are under the age of 18 or over the age of 65.

          -  Received or plans to receive licensed inactivated 2009 H1N1 influenza vaccine from 14
             days prior to 14 days after any study vaccination.

          -  Received or plans to receive any other licensed vaccines from 30 days prior to the
             first study vaccination until 30 days after the third study vaccination.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Gurwith, M.D., J.D.</last_name>
    <role>Study Director</role>
    <affiliation>PaxVax, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Pharmaceutical Research</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research Center, Inc.</name>
      <address>
        <city>Mt Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2009</study_first_submitted>
  <study_first_submitted_qc>November 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2009</study_first_posted>
  <last_update_submitted>June 27, 2013</last_update_submitted>
  <last_update_submitted_qc>June 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Virus Diseases</keyword>
  <keyword>Respiratory Tract Diseases</keyword>
  <keyword>Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

